U.S., Feb. 12 -- ClinicalTrials.gov registry received information related to the study (NCT06820723) titled 'A Mechanistic Study to Assess a Single Dose of CYB003 in Participants with Depression and Anxiety' on Jan. 29.
Brief Summary: The goal of this study is to learn how psychedelics may help symptoms of depression and anxiety. Participants with major depressive disorder experiencing symptoms of depression and anxiety will receive one dose of either a drug related to psilocybin or a placebo. Assessments include interviews, self-report questionnaires, EEG and fMRI to measure symptoms and brain function.
Study Start Date: March, 2025
Study Type: INTERVENTIONAL
Condition:
Depression
Anxiety
Major Depressive Disorder
Intervention:
DRUG...